Loading...
Market
What will be Pfizer's gross leverage position by the end of 2025?
3
Resolution / Starting Odds
Below 3.0x • 25%
3.0x - 3.25x • 25%
3.26x - 3.5x • 25%
Above 3.5x • 25%
Pfizer's official financial statements or disclosures
Story
Pfizer Projects 2025 Revenue of $61B-$64B, Adjusted EPS of $2.80-$3.00, Stock Rises 3%
Dec 17, 2024, 12:06 PM
Pfizer Inc. ($PFE) has provided its full-year guidance for 2025, projecting revenues between $61 billion and $64 billion, which aligns closely with Wall Street expectations of $63.23 billion. The company also anticipates adjusted diluted earnings per share (EPS) in the range of $2.80 to $3.00, slightly below the expected $2.90. Pfizer's guidance reflects an operational growth of 10% to 18% from the midpoint of its 2024 estimates. Additionally, the company plans to implement a manufacturing optimization program aimed at achieving $500 million in cost savings in 2025, building on an earlier $4 billion cost realignment strategy. The stock rose more than 3% in pre-market trading following the announcement, as the company seeks to address criticism regarding its turnaround strategy from activist hedge fund Starboard Value. Pfizer's gross leverage position is targeted at 3.25x, down from approximately 3.5x in the last quarter.
View original story
Similar markets
Less than 5% • 25%
5% to 5.5% • 25%
5.5% to 6% • 25%
Greater than 6% • 25%
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Less than $150 billion • 25%
$150 billion to $170 billion • 25%
$170 billion to $190 billion • 25%
More than $190 billion • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%